eli lilly glp-1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Eli Lilly's oral GLP-1 pill

Susan P Mollan, University of Birmingham, Institute of Metabolism and Systems Research, Birmingham, B15 2TT, UK

This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider

Epub 2023 Jul 17

The author holds equity interest in RNA Therapeutics Inc, DEI Biopharma Inc, Abyolo, and BioRx Inc, but none of these create any conflict of interest for this paper

The eldest of three sons of Jewish liberal parents, Samols' father was a doctor

Many of these drugs feature novel mechanisms of action or routes of administration and this increased competition may eventually exert downward pressure on pricing